Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)
Several other brokerages also recently commented on AZN. Deutsche Bank AG reduced their price target on shares of AstraZeneca plc from GBX 5,700 ($74.97) to GBX 5,300 ($69.71) and set a buy rating for the company in a research report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($53.93) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Tuesday, August 8th. Sanford C. Bernstein set a GBX 5,780 ($76.02) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Monday, September 25th. Barclays PLC reiterated an overweight rating and issued a GBX 6,300 ($82.86) target price on shares of AstraZeneca plc in a research report on Wednesday, July 26th. Finally, Societe Generale reiterated a buy rating on shares of AstraZeneca plc in a research report on Monday, September 11th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of Hold and an average price target of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (LON:AZN) traded up GBX 60 ($0.79) during trading hours on Thursday, hitting GBX 4,930 ($64.84). 2,560,000 shares of the company traded hands, compared to its average volume of 1,990,000. AstraZeneca plc has a fifty-two week low of GBX 3,996 ($52.56) and a fifty-two week high of GBX 5,520 ($72.60).
COPYRIGHT VIOLATION WARNING: “Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/shore-capital-reiterates-hold-rating-for-astrazeneca-plc-azn.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.